PT  - JOURNAL ARTICLE
AU  - Pierce, Carl A.
AU  - Sy, Sharlene
AU  - Galen, Benjamin
AU  - Goldstein, Doctor Y
AU  - Orner, Erika
AU  - Keller, Marla J.
AU  - Herold, Kevan C.
AU  - Herold, Betsy C.
TI  - Natural Mucosal Barriers and COVID-19 in Children
AID  - 10.1101/2021.02.12.21251310
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.12.21251310
4099  - http://medrxiv.org/content/early/2021/02/13/2021.02.12.21251310.short
4100  - http://medrxiv.org/content/early/2021/02/13/2021.02.12.21251310.full
AB  - COVID-19 is more benign in children compared to adults for unknown reasons. This contrasts with other respiratory viruses where disease manifestations are often more severe in children. We hypothesized that a more robust early innate immune response to SARS-CoV-2 may protect against severe disease and compared clinical outcomes, viral copies and cellular gene and protein expression in nasopharyngeal swabs from 12 children and 27 adults upon presentation to the Emergency Department. SARS-CoV-2 copies were similar, but compared to adults, children displayed higher expression of genes associated with interferon signaling, NLRP3 inflammasome, and other innate pathways. Higher levels of IFN-α2, IFN-γ, IP-10, IL-8, and IL-1β protein were detected in nasal fluid in children versus adults. Anti-SARS-CoV-2 IgA and IgG were detected in nasal fluid from both groups and correlated negatively with mucosal IL-18. These findings suggest that a vigorous mucosal immune response in children compared to adults contributes to favorable clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementR01 AI134367, UL1 TR002556, P30 AI124414, T32GM007288 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the Albert Einstein College of Medicine (IRB# 2020-11278). Written informed consent was obtained for NP samples not obtained from the Clinical Microbiology Laboratory.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be deposited in a public database and accession codes provided at time of publication.